“Welcome to Early stages of Parkinson’s disease”
Primary cortical neuron with staining for MAP2, TGN-46 and DAPI.
Primary cortical neuron with staining for PPP2CA and LRRK2.
CRISPR/Cas9 technology used in the lab to silence or activate transcription in human cells: dCas9-mediated transcriptional modulation of phosphatases.
(A) dCas9 fused to effector domains can serve as an RNA-guided DNA-binding protein to target any protein to any DNA sequence. The effectors used with the catalytically inactive Cas9 (dCas9) are KRAB fusion protein to repress (CRISPRi) or the VP64 fusion protein to activate (CRISPRa) expression has shown on the picture.
(B) Stable suppression and overexpression of PPP1R1B by dCas9-KRAB or dCas9-VP64 in SH-SY5Y cells respectively. Cells stably expressing dCas9-KRAB or VP64 were infected with lentivirus constructs expressing a negative control sgRNA or two different sgRNAs targeting PPP1R1B.
EARLY STAGES OF PARKINSON'S DISEASE
STAFF - ALUMNI
DEBROUCKER Amélie, PhD
EMANUELE Marco, PhD
LEPRETRE Frédéric, PhD
LARVOR Lydie, PhD
NKILIZA Aurore, PhD
GLORIAN SCHMITT Valérie, PhD
STIEVENARD Aliçia, PhD
TREVOR Tyson, PhD
VILTART Odile, PhD
WOLKOFF Nathalie, PhD
TRAINEESHIP
(Foreign researcher, Masters, Erasmus, Engineer, Technician, etc.)
ASSIBA Fatou, BTS
BAUDELEY Claire-Aline, Licence 3
BEEKHAREE Diana, Master 2
BONTE Marie-Amandine, Master 1
BOUGEOIS Paul, Master 2 Santé
CATSBURT Lisa, Master Erasmus, Nederland
DANENS Matthieu, DU- ITB
DIOP Fatou-Yali, Licence 3
FERNANDEZ LOPEZ Belén, Post-doctorant FEBS Fellowship, Spain
HOPES Lucie, M2 R, Thèse de médecine
LARA ORDONEZ Antonio Jesus, Master Erasmus, Spain.
LESUR Blandine, Licence 3
LEFEBVRE Jonathan, BTS
LEFEBVRE Réginald, IUT, Licence
LORGNIER Timothée, Master
MANIEZ Sophie, Licence 2 et 3, Master 2
PENET Justine, Master 1
PHAN Cécile, Master 2
SAITOSKI Kevin, Master 2
VAN LANDEGEM Antoine, Master 1
VERIN Justine, Master 2